Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and rela...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/968212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306796675563520 |
|---|---|
| author | Roberta Fedele Massimo Martino Anna Grazia Recchia Giuseppe Irrera Massimo Gentile Fortunato Morabito |
| author_facet | Roberta Fedele Massimo Martino Anna Grazia Recchia Giuseppe Irrera Massimo Gentile Fortunato Morabito |
| author_sort | Roberta Fedele |
| collection | DOAJ |
| description | Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minority of refractory patients. Patients progressing after intensive treatments, such as auto-SCT, have a very poor outcome. Allogeneic SCT represents the only strategy with a curative potential for these patients; however, its role is controversial. Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored. This review will discuss the clinical results regarding auto-SCT and allo-SCT as well as the current role of emerging new treatment strategies. |
| format | Article |
| id | doaj-art-276f3b4b62de4940a5aa3bb3d57257f3 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-276f3b4b62de4940a5aa3bb3d57257f32025-08-20T03:54:57ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/968212968212Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewRoberta Fedele0Massimo Martino1Anna Grazia Recchia2Giuseppe Irrera3Massimo Gentile4Fortunato Morabito5Hematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMM, 89100 Reggio Calabria, ItalyHematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMM, 89100 Reggio Calabria, ItalyBiotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, 87051 Aprigliano, ItalyHematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMM, 89100 Reggio Calabria, ItalyHematology Unit, Azienda Ospedaliera di Cosenza, 87100 Cosenza, ItalyBiotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, 87051 Aprigliano, ItalyHodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minority of refractory patients. Patients progressing after intensive treatments, such as auto-SCT, have a very poor outcome. Allogeneic SCT represents the only strategy with a curative potential for these patients; however, its role is controversial. Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored. This review will discuss the clinical results regarding auto-SCT and allo-SCT as well as the current role of emerging new treatment strategies.http://dx.doi.org/10.1155/2015/968212 |
| spellingShingle | Roberta Fedele Massimo Martino Anna Grazia Recchia Giuseppe Irrera Massimo Gentile Fortunato Morabito Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Journal of Immunology Research |
| title | Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review |
| title_full | Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review |
| title_fullStr | Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review |
| title_full_unstemmed | Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review |
| title_short | Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review |
| title_sort | clinical options in relapsed or refractory hodgkin lymphoma an updated review |
| url | http://dx.doi.org/10.1155/2015/968212 |
| work_keys_str_mv | AT robertafedele clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview AT massimomartino clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview AT annagraziarecchia clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview AT giuseppeirrera clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview AT massimogentile clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview AT fortunatomorabito clinicaloptionsinrelapsedorrefractoryhodgkinlymphomaanupdatedreview |